Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 16 |
| Active Pipeline (Recruiting Now) | 4 (4) |
| Completed vs Stopped Early | 2 / 1 (6.3%) |
| Median Closed Actual Enrollment | 11 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Chongqing University Cancer Hospital | Chongqing | 5 |
| Shanxi Bethune Hospital | Taiyuan | 2 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT05334823 | A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents | Phase II | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Chongqing Precision Biotech Co Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.